The potential treatments include ivermectin, methylene blue, glucagon-like peptide-1 receptor agonists, and low-dose naltrexone.
Valerie Richards, PharmD
Advertisement
Articles by Valerie Richards, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Interchangeability Designation to Denosumab Biosimilars Stoboclo and Osenvelt
2
Because Ned Said: America’s Growing Pharmacy Deserts Are Leaving Patients High and Dry
3
Meeting Patients Where They Are: How Pharmacists Are Helping People Stay on Track With Schizophrenia Treatment
4
Denosumab Biosimilars Conexxence and Bomyntra Receive Interchangeability Designation
5
